Digital Dose Inhaler Market Size, Share & Trends Analysis Report By Product (MDI, DPI), By Indication (Asthma, COPD), By Type (Branded Medication, Generic Medication), By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global digital dose inhaler market size was valued at USD 13.0 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 19.4% from 2023 to 2030. There is a growing demand for digital dose inhalers owing to the prevalence of chronic respiratory diseases, such as asthma, Chronic Obstructive Pulmonary Disease (COPD), and respiratory disorders. The increasing need to effectively monitor the date and time of dosing, which promotes collaborative care between clinics and patients, further contributes to the product demand. Moreover, the rising geriatric population suffering from both severe and mild respiratory disorders is another factor driving product demand. For instance, according to the United Nations Department of Economic and Social Affairs, the share of the population aged 65 years and above increased from 6% to 9% between 1990 to 2019.

The increasing per capita income as a result of the development in the fast-emerging economies, such as China, India, and Brazil, and the subsequent rise in disposable income are also expected to drive market growth in the coming years. The rise in cases of chronic respiratory diseases and the demand for technology-enabled respiratory devices will also support market growth. Inhalers are used to provide a reliable yet simple dose counter for asthma and COPD caused by smoking, poor quality of air, and exposure to occupational dust for people working in agriculture, forest, and mines. According to the Centers for Disease Control and Prevention (CDC), in 2021, nearly 11% of the adult population in the U.S. smoked cigarettes.

The efforts taken by various Non-Governmental Organizations (NGOs) and companies, in the form of programs, such as awareness camps about respiratory diseases, contribute to the adoption of inhalers. For instance, through various activities, Cipla runs a patient awareness campaign named Berok Zindagi through various activities in Kochi, India; Aster Medcity Pulmonology Department organized a free lung disease awareness camp on World COPD Day. Several technological advancements are revolutionizing inhalation therapy devices, including the Metered Dose Inhalers (MDIs) equipped with an e-dose counter and internet-connected and compact inhalers, among others that are spurring the growth of the digital dose inhaler.

Medical device manufacturers are focusing on connectivity technologies to improve patient medication adherence and ensure appropriate dosage administration. Furthermore, favorable reimbursement policies available to patients in the form of government-sponsored Medicare & Medicaid plans, individual insurance policies, group association policies, and employee policies are expected to boost the treatment rates for asthma, COPD, and other respiratory disorders; altogether, these developments will support the emergence of the market over the forecast period.

Medicare, a U.S. government insurance program, offers to cover medication and inhalers of beneficiaries affected by moderate to severe pulmonary disease. During the COVID-19 pandemic, patients suffering from asthma and COPD were at high risk of hospitalization due to infection. The increase in COVID-19 cases resulted in a rise in respiratory disorder cases boosting product demand. For instance, the U.S. CDC listed COPD and uncontrolled asthma as risk factors for severe COVID-19.

Type Insights

The branded medication segment accounted for the largest share in 2022 owing to a steep rise in the healthcare expenditure levels and a rise in demand for new respiratory medication development. The penetration of branded drugs is expected to increase due to the continuous investment by manufacturers in R&D activities. In 2020, GlaxoSmithKline plc of the UK and Innoviva, Inc. of the U.S. announced the U.S. Food and Drug Administration (FDA) approval for Trelegy Ellipta for treating asthma in patients aged 18 years and above.

The generic medication segment is expected to grow rapidly over the forecast period. The rising awareness regarding the same benefits of generic drugs as branded ones and the high demand for cost-effective medications are expected to significantly augment the segment's growth. In March 2022, the FDA approved the first generic drug for Symbicort: Breyna, used for treating asthma and COPD. The U.S. FDA approved Perrigo's abbreviated new drug application in February 2022 for generic albuterol sulfate inhalation aerosol, the first ProAir HFA replacement for receiving an AB rating.

Product Insights

The MDI product segment accounted for the largest revenue share of 63.8% in 2022 owing to increased healthcare expenditure and a rise in the cases of respiratory diseases.Moreover, consistent technological advances pertaining to the development of inhalation medication, such as mechanistic Pharmacokinetic/Pharmacodynamics (PK/PD) modeling, patient-feedback features in electronic monitoring systems, controlled-release formulations, and nanotechnology-based formulations with high drug loads enclosed in smaller dose sizes, are some of the pivotal factors involved in improving the therapeutic efficacy of the medication & impacting the overall patient compliance patterns that are expected to boost the product demand over the forecast period.

In 2020, Aptar Pharma, a drug delivery specialist company, collaborated with Lupin Ltd. to launch India’s first connection-enabled device for MDI. The Dry Powder Inhaler (DPI) segment is expected to register a significant CAGR of 18.7% from 2023 to 2030. DPI is better for users with low cognitive ability and needs no preparation. Concerns related to drug irritation caused by propellant components, such as Chlorofluorocarbons (CFCs) in MDI, have favored the adoption of DPIs, with fewer irritant effects, while delivering comparable therapeutic efficacy as MDIs. Moreover, increased R&D and the introduction of advanced & effective DPIs by industry players also drive the segment growth. For instance, in 2021, Glenmark Pharma introduced the Tiotropium Bromide DPI in the UK to treat COPD.

Indication Insights

The COPD segment dominated the global industry with a share of 50.40% of the overall revenue in 2022. The segment is expected to retain its dominance over the forecast period owing to the increasing incidence rate of COPD globally. Factors responsible for COPD include smoking, air pollution, dust, chemical fumes, and childhood infections. According to a report published by the World Health Organization (WHO) in March 2023, COPD was one of the leading causes of death worldwide in 2019.

Nearly 90% of deaths of those under 70 years of age occur in Low- and Middle-Income Countries (LMIC). The asthma segment is estimated to grow at a significant CAGR of 16.4% over the forecast period. According to the National Institute of Health, in 2019, around 300 million people were affected by asthma globally, and it is estimated to affect around 100 million people by 2050, making it a serious health problem. Therefore, an increase in the number of asthma patients is anticipated to be opportunistic for the market in the coming years.

Regional Insights

North America dominated the global industry in 2022 and accounted for the largest share of 45.6% of the overall revenue owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years. According to stats published in 2020 by the American Lung Association, approximately 5.0% of adults, or 12.5 million people, reported a diagnosis of COPD in the region.

Asia Pacific is expected to grow at the fastest CAGR of 21.2% during the forecast period. Japan and China constitute the key identified hubs for respiratory devices due to an increase in the aging population, high expenditure on healthcare, and evolving healthcare industry. According to the National Institutes of Health, in China, 4.2% or 45.7 million adults are reported to have asthma, making it a significant public health issue, whereas, in Japan, between 6% and 10% of adults are reported to have the disease.

Key Companies & Market Share Insights

The market is highly competitive and companies are undertaking strategies, such as product launches, approvals, strategic acquisitions, and innovations. In February 2022, Honeywell International Inc., an American multi-national company, and AstraZeneca plc, a multi-national pharmaceutical company, announced to develop respiratory inhalers by using HFO-1234ze propellant, which reduces Global Warming Potential (GWP) by 99.9% less than the propellants currently used in respiratory medicines.

Enerzair Breezhaler by Novartis AG, a Swiss pharmaceutical company, obtained European Commission’s (EC) approval, becoming the first digital asthma therapy in the EU to be prescribed coupled with a sensor and app. In September 2022, Teva Pharmaceutical Industries Ltd., introduced two digital inhalers in the U.S.: ArmonAir Digihaler (fluticasone propionate) and AirDuo Digihaler (fluticasone propionate and salmeterol). Some of the key companies operating in the global digital dose inhaler market include:

• 3M Company

• AstraZeneca Plc

• Glenmark Pharmaceuticals Ltd.

• Novartis AG

• Propeller Health

• Sensirion AG

• Opko Health, Inc.

• Teva Pharmaceutical Industries Ltd.

• BEXIMCO Pharmaceuticals

• GlaxoSmithKline Plc

• Mundipharma Deutschland GmbH & Co. KG

Digital Dose Inhaler Market Report Scope

Global Digital Dose Inhaler Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global digital dose inhaler market report based on product, type, indication, and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Metered Dose Inhaler (MDI)

  • Dry Powder Inhaler (DPI)

• Type (Revenue, USD Million, 2018 - 2030)

  • Branded Medication

  • Generic Medication

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Asthma

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait